# A Clinical Trial of a Prophylactic Plasmid DNA Vaccine for COVID-19 [Covigenix VAX-001] in Adults

> **NCT04591184** · PHASE1,PHASE2 · COMPLETED · sponsor: **Entos Pharmaceuticals Inc.** · enrollment: 268 (actual)

## Conditions studied

- SARS-CoV-2

## Interventions

- **BIOLOGICAL:** Covigenix VAX-001 placebo
- **BIOLOGICAL:** Covigenix VAX-001

## Key facts

- **NCT ID:** NCT04591184
- **Lead sponsor:** Entos Pharmaceuticals Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2021-04-07
- **Primary completion:** 2023-12-06
- **Final completion:** 2023-12-06
- **Target enrollment:** 268 (ACTUAL)
- **Last updated:** 2024-02-20

## Collaborators

- [object Object]
- [object Object]
- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04591184

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04591184, "A Clinical Trial of a Prophylactic Plasmid DNA Vaccine for COVID-19 [Covigenix VAX-001] in Adults". Retrieved via AI Analytics 2026-06-09 from https://api.ai-analytics.org/clinical/NCT04591184. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*